€6.23 -0.1 -1.6%
Last Trade - 12:12pm
| Market Cap | ÂŁ77.4m |
| Enterprise Value | ÂŁ57.6m |
| Revenue | ÂŁ9.47k |
| Position in Universe | 546th / 847 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.003 | 8.52 | 3.54 | 3.12 | 0.006 | 2.25 | -47.2% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | July 24, 2007 |
| Public Since | July 5, 2013 |
| No. of Shareholders: | n/a |
| No. of Employees: | 107 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Euronext - Brussels |
| Shares in Issue | 14,205,156 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Axis Business Park Rue Edouard Belin 2, MONT-SAINT-GUIBERT, 1435, Belgium |
| Web | https://www.celyad.com/ |
| Phone | +32 10 394100 |
| Contact | () |
| Auditors | BDO Reviseurs d Entreprises |
As of 12:12pm, shares in Celyad Oncology are trading at €6.23, giving the company a market capitalisation of £77.4m. This share price information is delayed by 15 minutes.
Shares in Celyad Oncology are currently trading at €6.23 and the price has moved by -23.37% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celyad Oncology price has moved by -30.81% over the past year.
Of the analysts with advisory recommendations for Celyad Oncology, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Celyad Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Celyad Oncology is scheduled to issue upcoming financial results on the following dates:
Celyad Oncology does not currently pay a dividend.
Celyad Oncology does not currently pay a dividend.
Celyad Oncology does not currently pay a dividend.
To buy shares in Celyad Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Celyad Oncology are currently trading at €6.23, giving the company a market capitalisation of £77.4m.
Here are the trading details for Celyad Oncology:
Based on an overall assessment of its quality, value and momentum, Celyad Oncology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Celyad Oncology are currently priced at €6.23. At that level they are trading at 0.127% discount to the analyst consensus target price of 0.00.
Analysts covering Celyad Oncology currently have a consensus Earnings Per Share (EPS) forecast of -2.087 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celyad Oncology. Over the past six months, the relative strength of its shares against the market has been -30.95%. At the current price of €6.23, shares in Celyad Oncology are trading at -20.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Celyad Oncology.
Celyad Oncology's management team is headed by:
Here are the top five shareholders of Celyad Oncology based on the size of their shareholding:
